Mertk Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S7342	UNC2250	UNC2250 is a potent and selective Mer inhibitor with IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.	Journal of Hematology & Oncology, March 20, 2018, 43 Bioact Mater, 2024, 32:427-444 Redox Biol, 2022, 54:102366
S7325	UNC2881	UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively.	Frontiers in Bioengineering and Biotechnology, 2022, 788987 Cell Rep, 2020, 30(11):3671-3681 Cell Reports, 2020, 3671-3681
S6839	MRX-2843	MRX-2843 (UNC2371) is an orally active dual inhibitor of tyrosine kinases MERTK and FLT3 with IC50 of 1.3 nM and 0.64 nM, respectively.	Cancer Immunology Research, 2025, CIR-24-0335 Scientific Reports, 2024, 4125 Scientific Reports, 2024, 14:4125
E1744	UNC5293	UNC5293 is a potent, highly selective, orally available inhibitor of MER receptor tyrosine kinase (MERTK) with IC50 of 0.9 nM and Ki 0.19 nM.	Nature Communications, 2024, 5292
S0439	UNC2541	UNC2541 is a potent and specific inhibitor of Mer tyrosine kinase (MerTK) that binds in the MerTK ATP pocket with IC50 of 4.4 nM. This compound inhibits phosphorylated MerTK (pMerTK) with EC50 of 510 nM.
S7638	LDC1267	LDC1267 is a highly selective TAM kinase inhibitor with IC50 of <5 nM, 8 nM, and 29 nM for Mer, Tyro3, and Axl, respectively. This compound displays lower activity against Met, Aurora B, Lck, Src, and CDK8.	Genes & Development, October 1, 2020, 1345-1358 Frontiers in Microbiology, June 29, 2020, 1292 Oncotarget, January 5, 2018, 6402-6415
S7576	UNC2025 HCl	UNC2025 HCl is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.	bioRxiv, 2025, 2025.07.18.665641 Immunity, 2023, 56(8):1778-1793.e10 International Journal of Molecular Sciences, 2023, 15903
S7014	Merestinib (LY2801653)	Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of Met (c-Met) tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. This compound also inhibits MST1R, AXL, ROS1, MKNK1/2, FLT3, MERTK, DDR1 and DDR2 with IC50 of 11 nM, 2 nM, 23 nM, 7 nM, 7 nM, 10 nM, 0.1 nM and 7 nM, respectively.	Mol Oncol, 2025, 19(8):2366-2387 Molecular Oncology, 2025, 2366-2387 NPJ Breast Cancer, 2024, 10(1):65
S8570	CEP-40783 (RXDX-106)	CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.	Cell Reports, October 05, 2021, 109789 Journal of Clinical Investigation, November 01, 2018, 5034-5055 UNIVERSITY OF CALIFORNIA, 2023,
S9662	UNC2025	UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. This compound also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.	iScience, 2024, 27(7):110226 Commun Biol, 2023, 6(1):916 Int J Mol Sci, 2023, 10.3390/ijms242115903
S8933	Tamnorzatinib (ONO-7475)	Tamnorzatinib (ONO-7475) is a potent, selective, and orally active novel inhibitor of Anexelekto(Axl)/MER tyrosine kinase with IC50 of 0.7 nM and 1.0 nM for AXL and MER, respectively. This compound suppresses the emergence and maintenance of tolerant cells to the initial EGFR-TKIs, osimertinib or dacomitinib, in AXL-overexpressing EGFR-mutated NSCLC cells. It also arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells.	Acta Pharmacologica Sinica, November 30, 2022, 984-998 JTO Clinical and Research Reports, May 12, 2023, 100525 Neuro-Oncology, June 21, 2025, 1372-1384
S8404	S49076	S49076 is a novel, potent inhibitor of Met (c-Met), AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.	Mol Brain, 2020, 4;13(1):66
S0071	RU-301	RU-301 is a pan-TAM receptor (Axl, Tyro3 and Mertk) inhibitor that blocks the Axl receptor dimerization site with Kd of 12 μM and IC50 of 10 μM, respectively.
E0142	XL092	XL092 (JUN04542) is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays, respectively.